Cargando…

Protective Effects of the Wenfei Buqi Tongluo Formula on the Inflammation in Idiopathic Pulmonary Fibrosis through Inhibiting the TLR4/MyD88/NF-κB Pathway

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with high mortality and poor prognosis. The prognostic signatures related to conventional therapy response remain limited. The Wenfei Buqi Tongluo (WBT) formula, a traditional Chinese medicine (TCM) formula, has been widely uti...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Siyu, Wang, Jing, Liu, Guanwen, Ding, Lu, Li, Yaxin, Qi, Hongyu, Wei, Lai, Zhao, Jiachao, Chen, Tian, Zhao, Meiru, Wang, Ziyuan, Yang, Yingying, Zhao, Daqing, Li, Xiangyan, Wang, Zeyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843962/
https://www.ncbi.nlm.nih.gov/pubmed/35178456
http://dx.doi.org/10.1155/2022/8752325
_version_ 1784651379919290368
author Song, Siyu
Wang, Jing
Liu, Guanwen
Ding, Lu
Li, Yaxin
Qi, Hongyu
Wei, Lai
Zhao, Jiachao
Chen, Tian
Zhao, Meiru
Wang, Ziyuan
Yang, Yingying
Zhao, Daqing
Li, Xiangyan
Wang, Zeyu
author_facet Song, Siyu
Wang, Jing
Liu, Guanwen
Ding, Lu
Li, Yaxin
Qi, Hongyu
Wei, Lai
Zhao, Jiachao
Chen, Tian
Zhao, Meiru
Wang, Ziyuan
Yang, Yingying
Zhao, Daqing
Li, Xiangyan
Wang, Zeyu
author_sort Song, Siyu
collection PubMed
description BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with high mortality and poor prognosis. The prognostic signatures related to conventional therapy response remain limited. The Wenfei Buqi Tongluo (WBT) formula, a traditional Chinese medicine (TCM) formula, has been widely utilized to treat respiratory diseases in China, which is particularly effective in promoting inflammatory absorption. In this study, we aim to explore the mechanism of the WBT formula in the inhibition of inflammatory response during IPF, based on network pharmacology and in vivo experiments. METHODS: Network pharmacology was applied to predict the changes of biological processes and potential pathways for the WBT formula against IPF. Histopathological changes, inflammatory factors (IL-6, IL-1β, and TNF-α), and the proteins of the TLR4/MyD88/NF-κB pathway in bleomycin- (BLM-) induced mice model were examined by hematoxylin-eosin (H&E), Masson or immunohistochemistry staining, Western blot, and enzyme-linked immunosorbent assay analysis. RESULTS: A total of 163 possible components and 167 potential targets between the WBT formula and IPF were obtained. The enrichments of network pharmacology showed that inflammation response, TNF, and NF-κB pathways were involved in the treatment of WBT against IPF. The in vivo experiments indicated that the WBT formula could ameliorate inflammatory exudation and collagen deposition at a histopathology level in the BLM-induced mice model. The levels of IL-6, IL-1β, and TNF-α were reduced after the WBT formula treatment. Moreover, the expressions of phosphorylated-NF-κB p65, TLR4, and MyD88 were significantly downregulated by the WBT formula, compared with the BLM-induced group. CONCLUSION: These results indicated that the WBT formula can suppress BLM-induced IPF in a mouse model by inhibiting the inflammation via the TLR4/MyD88/NF-κB pathway. This study provides a new insight into the molecular mechanisms of the WBT formula in the application at the clinic.
format Online
Article
Text
id pubmed-8843962
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-88439622022-02-16 Protective Effects of the Wenfei Buqi Tongluo Formula on the Inflammation in Idiopathic Pulmonary Fibrosis through Inhibiting the TLR4/MyD88/NF-κB Pathway Song, Siyu Wang, Jing Liu, Guanwen Ding, Lu Li, Yaxin Qi, Hongyu Wei, Lai Zhao, Jiachao Chen, Tian Zhao, Meiru Wang, Ziyuan Yang, Yingying Zhao, Daqing Li, Xiangyan Wang, Zeyu Biomed Res Int Research Article BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with high mortality and poor prognosis. The prognostic signatures related to conventional therapy response remain limited. The Wenfei Buqi Tongluo (WBT) formula, a traditional Chinese medicine (TCM) formula, has been widely utilized to treat respiratory diseases in China, which is particularly effective in promoting inflammatory absorption. In this study, we aim to explore the mechanism of the WBT formula in the inhibition of inflammatory response during IPF, based on network pharmacology and in vivo experiments. METHODS: Network pharmacology was applied to predict the changes of biological processes and potential pathways for the WBT formula against IPF. Histopathological changes, inflammatory factors (IL-6, IL-1β, and TNF-α), and the proteins of the TLR4/MyD88/NF-κB pathway in bleomycin- (BLM-) induced mice model were examined by hematoxylin-eosin (H&E), Masson or immunohistochemistry staining, Western blot, and enzyme-linked immunosorbent assay analysis. RESULTS: A total of 163 possible components and 167 potential targets between the WBT formula and IPF were obtained. The enrichments of network pharmacology showed that inflammation response, TNF, and NF-κB pathways were involved in the treatment of WBT against IPF. The in vivo experiments indicated that the WBT formula could ameliorate inflammatory exudation and collagen deposition at a histopathology level in the BLM-induced mice model. The levels of IL-6, IL-1β, and TNF-α were reduced after the WBT formula treatment. Moreover, the expressions of phosphorylated-NF-κB p65, TLR4, and MyD88 were significantly downregulated by the WBT formula, compared with the BLM-induced group. CONCLUSION: These results indicated that the WBT formula can suppress BLM-induced IPF in a mouse model by inhibiting the inflammation via the TLR4/MyD88/NF-κB pathway. This study provides a new insight into the molecular mechanisms of the WBT formula in the application at the clinic. Hindawi 2022-02-07 /pmc/articles/PMC8843962/ /pubmed/35178456 http://dx.doi.org/10.1155/2022/8752325 Text en Copyright © 2022 Siyu Song et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Song, Siyu
Wang, Jing
Liu, Guanwen
Ding, Lu
Li, Yaxin
Qi, Hongyu
Wei, Lai
Zhao, Jiachao
Chen, Tian
Zhao, Meiru
Wang, Ziyuan
Yang, Yingying
Zhao, Daqing
Li, Xiangyan
Wang, Zeyu
Protective Effects of the Wenfei Buqi Tongluo Formula on the Inflammation in Idiopathic Pulmonary Fibrosis through Inhibiting the TLR4/MyD88/NF-κB Pathway
title Protective Effects of the Wenfei Buqi Tongluo Formula on the Inflammation in Idiopathic Pulmonary Fibrosis through Inhibiting the TLR4/MyD88/NF-κB Pathway
title_full Protective Effects of the Wenfei Buqi Tongluo Formula on the Inflammation in Idiopathic Pulmonary Fibrosis through Inhibiting the TLR4/MyD88/NF-κB Pathway
title_fullStr Protective Effects of the Wenfei Buqi Tongluo Formula on the Inflammation in Idiopathic Pulmonary Fibrosis through Inhibiting the TLR4/MyD88/NF-κB Pathway
title_full_unstemmed Protective Effects of the Wenfei Buqi Tongluo Formula on the Inflammation in Idiopathic Pulmonary Fibrosis through Inhibiting the TLR4/MyD88/NF-κB Pathway
title_short Protective Effects of the Wenfei Buqi Tongluo Formula on the Inflammation in Idiopathic Pulmonary Fibrosis through Inhibiting the TLR4/MyD88/NF-κB Pathway
title_sort protective effects of the wenfei buqi tongluo formula on the inflammation in idiopathic pulmonary fibrosis through inhibiting the tlr4/myd88/nf-κb pathway
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843962/
https://www.ncbi.nlm.nih.gov/pubmed/35178456
http://dx.doi.org/10.1155/2022/8752325
work_keys_str_mv AT songsiyu protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT wangjing protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT liuguanwen protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT dinglu protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT liyaxin protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT qihongyu protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT weilai protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT zhaojiachao protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT chentian protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT zhaomeiru protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT wangziyuan protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT yangyingying protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT zhaodaqing protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT lixiangyan protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway
AT wangzeyu protectiveeffectsofthewenfeibuqitongluoformulaontheinflammationinidiopathicpulmonaryfibrosisthroughinhibitingthetlr4myd88nfkbpathway